VIREMED
ActiveVIREMED has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €468k and a net result of €107k. Equity is growing by ~29.7% per year across the filed fiscal years. Its solvency ranks better than 64% of 16511 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2025
94
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability90▼-3
Solvency100=
Growth78=
Track record100
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40k at 30 days acceptable
Liquidity ample (current ratio 4.12 against 11.46 in 2024; short-term debt: 24.2% and cash: 73.3% of total assets), and 24.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
75.8%
Return on assets
17.3%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-06-2026, 51 days ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
51 d early
2024
28 d late
2023
2 d early
2022
30 d late
2021
31 d late
2020
27 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
20-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€468k▲ 8.3%
2024 · €432k
2020: €76k
2021: €165k
2022: €256k
2023: €342k
2024: €432k
2020 → 2025
Total assets
€618k▲ 30.8%
2024 · €473k
2020: €119k
2021: €255k
2022: €388k
2023: €415k
2024: €473k
2020 → 2025
Net result
€107k▲ 18.3%
2024 · €90k
2020: €71k
2021: €89k
2022: €91k
2023: €91k
2024: €90k
2020 → 2025
Working capital
€468k▲ 10.6%
2024 · €423k
2020: €76k
2021: €132k
2022: €229k
2023: €324k
2024: €423k
2020 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€165k-€256k▲ 55.3%€342k▲ 33.7%€432k▲ 26.4%€468k▲ 8.3%
Operating result€126k-€130k▲ 3.3%€127k▼ 2.2%€127k▼ 0.5%€143k▲ 12.9%
Net result€89k-€91k▲ 2.2%€91k▲ 0.2%€90k▼ 1.3%€107k▲ 18.3%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 13% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €618k
Fixed assets
€768▼ 91.8%
Current assets
€617k▲ 33.2%
Equity and liabilities €618k
Equity
€468k▲ 8.3%
Debt
€150k▲ 270%
The debt ratio rises from 8.6% to 24.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€152k▲
2024 · €135k
Cash flow
€115k▲
2024 · €99k
Solvency
75.8%▼
2024 · 91.4%
Current ratio
4.12▼
2024 · 11.46
Quick ratio
4.12▼
2024 · 11.46
Debt / equity
0.32▲
2024 · 0.09
ROE
22.8%▲
2024 · 20.9%
ROA
17.3%▼
2024 · 19.1%
Interest coverage
73.26▲
2024 · 42.92
Debt
€150k▲
2024 · €40k
Debt ≤ 1 year
€150k▲
2024 · €40k
Income taxes
€44k▲
2024 · €36k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€473k€618k▲
Fixed assets21/28€9k€768▼
Tangible fixed assets22/27€9k€768▼
Plant, machinery and equipment23€958€533▼
Furniture and vehicles24€8k€235▼
Current assets29/58€463k€617k▲
Amounts receivable within one year40/41€13k€11k▼
Trade receivables40€6k€5k▼
Other amounts receivable41€7k€6k▼
Current investments50/53€226k€152k▼
Cash at bank and in hand54/58€224k€453k▲
Deferred charges and accrued income490/1€167€440▲
Equity and liabilities
Total equity and liabilities10/49€473k€618k▲
Equity10/15€432k€468k▲
Contributions10/11€5k€5k=
Reserves13€427k€463k▲
Distributable reserves133€427k€463k▲
Profit (loss) carried forward14€0€0=
Amounts payable17/49€40k€150k▲
Amounts payable within one year42/48€40k€150k▲
Trade debts44€16k€52k▲
Suppliers440/4€16k€52k▲
Taxes, remuneration and social security45€6k€9k▲
Taxes450/3€4k€9k▲
Remuneration and social security454/9€2k€0▼
Other amounts payable47/48€18k€90k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€9k€9k▼
Other operating charges640/8€449€515▲
Gross operating margin9900€136k€152k▲
Operating profit (loss)9901€127k€143k▲
Financial income75/76B€3k€9k▲
Recurring financial income75€3k€9k▲
Financial charges65/66B€3k€2k▼
Recurring financial charges65€3k€2k▼
Profit (loss) for the period before taxes9903€126k€150k▲
Income taxes67/77€36k€44k▲
Profit (loss) for the period9904€90k€107k▲
Profit (loss) for the period to be appropriated9905€90k€107k▲
Appropriation of the result
Profit (loss) to be appropriated9906€90k€107k▲
Transfer from equity791/2-€71k
Transfer to equity691/2€90k€107k▲
To other reserves6921€90k€107k▲
Profit to be distributed694/7€0€71k▲
Return on contributions (dividend)694-€71k
Directors or managers695€0-
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
10-06
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2020net €107k ▲18.3%
Operating result €143k, net result €107k, both a record.
28-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 28 days late
2024
31-12
Financial
Liquidity doublescurrent ratio 11.46
Current ratio from 5.46 to 11.46; short-term debt falls from €73k to €40k.
29-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
30-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 30 days late
2022
31-12
Financial
Equity above €200kEq €256k ▲55.3%
3 profitable years in a row build equity to €256k.
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
31-12
Financial
Equity above €150kEq €165k ▲118%
2 profitable years in a row build equity to €165k.
27-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 27 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Dilsen-Stokkem · 1 establishment unit since 2020
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Molenveld 613650 Dilsen-StokkemGround area
6,554 m²
Building footprint
1,237 m²
Volume, LiDAR
6,893 m³
2 parcels, Flanders · tallest building 14.7 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
VIREMED
since 20202.298.171.114
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 73043A0173/00H000 | Flanders | 5,057 m² | 1 · 1,020 m² | 14.7 m · 1 fl. |
| 73081C0321/00C000 | Flanders | 1,497 m² | 1 · 217 m² | - |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Cabinet Médical de la Haute Lesse
BE 0842.493.795
Tellin · Eq €468k
Dr. L. JANSSEN
BE 0545.971.032
Lummen · Eq €468k
DR. CALLANT EWOUT
BE 0791.733.004
Gent · Eq €468k
Centre de Médecine Héraclès
BE 0848.400.503
Binche · Eq €468k
DR. ERIK PEETERS
BE 0437.001.133
Antwerpen · Eq €469k
Of 9,124 companies in sector 86210 we hold annual accounts for 6,337. 4,942 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded15-01-2020
Fiscal year end31-12
Activities, NACEBEL
86210General medical practice
86909Human health activities
86995Nutrition and dietetics services
Sources
Crossroads Bank for EnterprisesNational Bank · 6 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.